Frontier Biotechnologies (SHSE:688221) - Stock Price, News & Analysis

688221 Stock Overview

A commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. More details

688221 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings have declined by 11.5% per year over past 5 years

Frontier Biotechnologies Inc. Competitors

Lifecome BiochemistryLtd

SZSE:002868

CN¥2.5b

Jiangsu Aidea Pharmaceutical

SHSE:688488

CN¥3.9b

Xinjiang Tianshan Animal Husbandry Bio-engineering

SZSE:300313

CN¥2.0b

Shanghai MicuRx Pharmaceutical

SHSE:688373

CN¥3.3b

Price History & Performance

Summary of all time highs, changes and price drops for Frontier Biotechnologies
Historical stock prices
Current Share Price	CN¥7.43
52 Week High	CN¥11.29
52 Week Low	CN¥4.48
Beta	0.81
11 Month Change	19.07%
3 Month Change	50.40%
1 Year Change	-34.01%
33 Year Change	-63.52%
5 Year Change	n/a
Change since IPO	-75.16%

Recent updates

Shareholder Returns

	688221	CN Biotechs	CN Market
7D	2.5%	-2.6%	-2.1%
1Y	-34.0%	-20.9%	2.8%

Return vs Industry: 688221 underperformed the CN Biotechs industry which returned -20.9% over the past year.

Return vs Market: 688221 underperformed the CN Market which returned 2.8% over the past year.

Price Volatility

Is 688221's price volatile compared to industry and market?
688221 volatility
688221 Average Weekly Movement	9.5%
Biotechs Industry Average Movement	8.9%
Market Average Movement	8.3%
10% most volatile stocks in CN Market	12.6%
10% least volatile stocks in CN Market	5.6%

Stable Share Price: 688221 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688221's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	395	C. J. Wang	www.frontierbiotech.com

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS.

Frontier Biotechnologies Inc. Fundamentals Summary

How do Frontier Biotechnologies's earnings and revenue compare to its market cap?
688221 fundamental statistics
Market cap	CN¥2.78b
Earnings (TTM)	-CN¥279.96m
Revenue (TTM)	CN¥133.67m

20.8x

P/S Ratio

-9.9x

P/E Ratio

Is 688221 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688221 income statement (TTM)
Revenue	CN¥133.67m
Cost of Revenue	CN¥84.16m
Gross Profit	CN¥49.51m
Other Expenses	CN¥329.47m
Earnings	-CN¥279.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Nov 25, 2024

Earnings per share (EPS)	-0.75
Gross Margin	37.04%
Net Profit Margin	-209.43%
Debt/Equity Ratio	39.0%

How did 688221 perform over the long term?

See historical performance and comparison

688221 Stock Overview

Risk Analysis

Frontier Biotechnologies Inc. Competitors

SZSE:002868

CN¥2.5b

SHSE:688488

CN¥3.9b

SZSE:300313

CN¥2.0b

SHSE:688373

CN¥3.3b

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

Shareholder Returns

Price Volatility

About the Company

Frontier Biotechnologies Inc. Fundamentals Summary

20.8x

-9.9x

Earnings & Revenue